Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant pertuzumab + trastuzumab with anthracycline- or non-anthracycline-based chemotherapy in HER2-positive breast cancer
2009-012019-17Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pertuzumab and trastuzumab in breast cancer and inflammatory breast cancer (IBC) (3 arms), sponsored by Roche. Primary endpoints: Tolerability during neoadjuvant treatment, Incidence of symptomatic cardiac events and 1 more. Started Jul 2009; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancerinflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2009-012019-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012019-17.